Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

    Kai Wucherpfennig, MD, PhD

    Chair, Department of Cancer Immunology and Virology
    Director, Center for Cancer Immunotherapy Research
    Professor of Neurology, Brigham and Women's Hospital and Harvard Medical School
    Professor of Microbiology and Immunobiology, Department of Microbiology and Immunobiology, Harvard Medical School

    About Wucherpfennig Lab

    Innovative research in T cell biology and cancer immunology

    T cells have the unique capacity to specifically detect and selectively destroy cancer cells based on T cell receptor-driven recognition of tumor antigens. All therapeutic approaches that have shown efficacy in the clinic are fundamentally based on enhancing the function of cytotoxic T cells. The Wucherpfennig lab aims to develop the next generation of cancer immunotherapies by in-depth mechanistic studies that identify the critical molecular switches controlling the ability of T cells to destroy cancers in highly immunosuppressive tumor microenvironments.

    We recently reported a novel in vivo approach that enables discovery of negative regulators of T cell function in tumors. The genes we discovered provide exciting opportunities to mechanistically understand key regulatory mechanisms in T cells. Furthermore, they provide an opportunity to enhance the anti-tumor activity of adoptive T cell therapies, for example with T cells that express a chimeric antigen receptor (CAR).

    We have also developed novel approaches to investigate immune responses in patients responding to cancer immunotherapies. A subset of patients generates antibodies against immunosuppressive molecules, and we developed a technique for isolation of memory B cells that produce such antibodies. A single cell PCR procedure provides the sequences of the antibody heavy and light chain genes, enabling production of recombinant antibodies for in depth mechanistic studies. We have found that such patient-derived antibodies can have intriguing functional properties and strong anti-tumor activity in humanized mouse models. This approach thereby enables us to directly learn from patients who respond to cancer immunotherapies and to develop human therapeutic antibodies.